Arsenal Biosciences cuts ‘majority’ of staff in move to in vivo CAR-T

Summary

Arsenal Biosciences is conducting a second major workforce reduction, cutting the majority of staff as it pivots its focus to in vivo CAR-T development. This follows a previous 50% headcount reduction approximately one year prior.